Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 18

Koebner Phenomenon Is an Indicator of Vitiligo Activity and Aggression [Letter]

Authors Tan Y ORCID logo, Zeng Y, Li R

Received 15 February 2025

Accepted for publication 19 February 2025

Published 21 February 2025 Volume 2025:18 Pages 443—444

DOI https://doi.org/10.2147/CCID.S522969

Checked for plagiarism Yes

Editor who approved publication: Dr Monica K. Li



Yingjian Tan,1 Yue Zeng,2 Rui Li1

1Department of Dermatology, Fuzhou First General Hospital, Fuzhou, People’s Republic of China; 2Department of Pathology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People’s Republic of China

Correspondence: Rui Li, Email [email protected]


View the original paper by Dr Tang and colleagues


Dear editor

We recently read with great interest the article “Correlation Between the Koebner Phenomenon and Clinical Features in Vitiligo” by Tang1 et al, published in your journal. This study presents that the Koebner phenomenon is associated with clinical progression, the acrofacial type, comorbid immune-related disease, and a larger lesion area of Vitiligo patients and may indicate disease activity and aggression.

The research collected 1472 Vitiligo patients from the Institute of Dermatology, Anhui Medical University and record their clinical manifestations of them. It divided the patients into two groups Koebner-positive and Koebner-negative and further compared the clinical characteristics of the two cohorts. As a result, no significant difference could be seen in age, age onset, gender, or family history between Koebner-positive and Koebner-negative groups, while the duration of disease, the percentage of patients in the progressive stage, with the acrofacial type, with comorbid immune-related diseases, with lesion area are higher in Koebner-positive group.

However, there are still some limitations in this project. Firstly, the research does not pay sufficient attention to the effect of environmental and psychological factors, which also play key roles in the progress of Vitiligo. The researchers are supposed to collect the information of the patients such as living environment, workplace, attitude towards their own illness, and expectations about the prognosis of the disease. Secondly, this was a single-center study, and ethnicities local diet, and climate may have biased the results. A multiple-center project that contains more hospitals from different cities in China will be more convincing. Lastly, the research merely focuses on the correlation between the Koebner Phenomenon and the Clinical Features of Vitiligo. The Mendelian Randomization can be used to explore the causal effect between them through the form of single nucleotide polymorphisms, providing genetic evidence for the research of Vitiligo.2,3

In conclusion, the work by Tang et al provides novel insights into the correlation between the Koebner phenomenon and Clinical characteristics of Vitiligo. However, further effort should be placed into decreasing the effect of confounding factors and exploring the genetic causal evidence between the Koebner phenomenon and Vitiligo.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Tang X, Hao C, Fan M, et al. Correlation between the koebner phenomenon and clinical features in vitiligo. Clin Cosmet Invest Dermatol. 2025;18.

2. Yang J, Lin W, Ma Y, et al. Investigation of the causal association between parkinson’s disease and autoimmune disorders: a bidirectional Mendelian randomization study. Front Immunol. 2024;15:1370831. doi:10.3389/fimmu.2024.1370831

3. Kang T-J, Lee SY, Yoon S, et al. PCSK9 inhibitors and the risk of vitiligo: a Mendelian randomization study. J Invest Dermatol. 2024. doi:10.1016/j.jid.2024.07.021

Creative Commons License © 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.